陆劲松-福州-乳腺癌的内分泌治疗进展.pptVIP

* SPEAKER’S NOTES This slide summarizes the events contributing to disease-free survival for the IES trial. Overall, there were fewer first events contributing to DFS were for exemestane (354) than for tamoxifen (454). The total number of events in this analysis was 808. Exemestane reduces both distant and local recurrences as well as the incidence of contralateral breast cancer. In this setting, distant recurrences are more common than local recurrences. The number of non breast cancer deaths (intercurrent deaths) is also lower for exemestane. Reference 1. Coombes, et al. First mature surv